Despite no hard evidence for the survival benefit of CRP in oligometastatic prostate cancer, several retrospective and prospective studies have suggested that CRP reduces the risk of clinical progression and improves long-term survival in patients with oligometastatic prostate cancer (3–6, 13). This evidence concerns the gene CRP and prostate cancer.